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HO-1Hereditary tyrosinemia type 1 (HT1) is the most severe inherited metabolic disease of the tyrosine catabolic
pathway, with a progressive hepatic and renal injury and a fatal outcome if untreated. Toxicmetabolites accumu-
lating in HT1 have been shown to elicit endoplasmic reticulum (ER) stress response, and to induce chromosomal
instability, cell cycle arrest and apoptosis perturbation. Althoughmany studies have concentrated on elucidating
these events, the molecular pathways responsible for development of hepatocellular carcinoma (HCC) still re-
main unclear. In this study the fah knockoutmurinemodel (fah−/−) was used to investigate the cellular signaling
implicated in the pathogenesis of HT1. Fah−/−mice were subjected to drug therapy discontinuation (Nitisinone
withdrawal), and livers were analyzed at different stages of the disease. Monitoring of mice revealed an increas-
ing degeneration of the overall physiological conditions following drug withdrawal. Histological analysis un-
veiled diffuse hepatocellular damage, steatosis, oval-like cells proliferation and development of liver cell
adenomas. Immunoblotting results revealed a progressive and chronic activation of stress pathways related to
cell survival and proliferation, including several stress regulators such as Nrf2, eIF2α, CHOP, HO-1, and some
members of theMAPK signaling cascade. Impairment of stress defensive mechanisms was also shown bymicro-
array analysis in fah−/−mice following prolonged therapy interruption. These results suggest that a sustained ac-
tivation of stress pathways in the chronic HT1 progression might play a central role in exacerbating liver
degeneration.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Hereditary tyrosinemia type 1 (HT1, OMIM 276700) is a severe
autosomal recessive disorder characterized by impairment of
fumarylacetoacetate hydrolase (FAH), the last enzyme in tyrosine deg-
radation pathway (Fig. 1). FAH ismainly expressed in liver and kidneys,
and loss of its activity results in accumulation of toxic metabolites such
as fumarylacetoacetate (FAA) and succinylacetone (SA), leading to a
progressive deterioration of renal and hepatic functions [1–8]. HT1
arises early in childhood and presents three different clinical forms:
acute, subacute and chronic [9]. The acute form is characterized by
lethal hepatic failure associatedwith cirrhosis, hepato- and splenomeg-
aly, leading to death in the ﬁrst months of life. The subacute formellulaire et Développementale,
) et PROTEO, Dép. de Biologie
CE-Marchand, 1030 Avenue de
Tanguay).(second half of the ﬁrst year) manifests a similar but less severe clinical
picture presenting usually with failure to thrive, hepatomegaly, easy
bruising and hypophosphatemic rickets (due to a tubular dysfunction).
In the chronic form (after theﬁrst year) patients show renal and hepatic
dysfunction, vitamin-D resistant rickets, growth retardation, neurologi-
cal crisis and hepatocellular carcinoma (HCC). The toxic actions of FAA
are thought to be responsible for renal and hepatic failure as well as
for the development of HCC [5,10–12]. Indeed several studies have re-
ported FAA as a mutagenic and apoptogenic compound [5,10,11], and
as cause of oxidative damage by forming stable adductwith glutathione
(GSH) and sulphydryl groups of proteins [13,14]. In addition, FAA
induces tumor hypoxia [15] and genomic instability [5,16]. Still
further contribution to the establishment of the sustained stress envi-
ronment is the alkylating capacity of FAA and maleylacetoacetate
(MAA) reduction products, fumarylacetone (FA) and maleylacteone
(MA) [17]. Accumulation of toxic products in liver and kidney cells
can be prevented by treating HT1 patients with NTBC (2-[2-nitro-4-
(triﬂuoromethyl)benzoyl]cyclohexane-1,3-dione, or Nitisinone), an in-
hibitor of p-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme
upstream of FAA production (Fig. 1). Currently, NTBC therapy, in
Fig. 1. The ﬁve enzymatic reactions of the tyrosine catabolic pathway. The GSH non-
enzymatic bypass for transformation ofMAA into FAA is also indicated. δ-ALAD is inhibited
by succinylacetone causing δ-ALA accumulation and inhibition of heme biosynthesis. TAT,
tyrosine aminotransferase; PLP, pyridoxal phosphate; PMP, pyridoxamine phosphate;
HPPD, 4-hydroxyphenylpyruvate dioxygenase; HGO, homogentisate dioxygenase; MAAI,
maleylacetoacetate isomerase; FAH, fumarylacetoacetate hydrolase; NTBC, 2-(2-nitro-4-
(triﬂuoromethyl)benzoyl)cyclohexane-1,3-dione; δ-ALAD, δ-aminolevulinic acid
dehydratase. Marked FAH indicates loss of function of this enzyme in HT1 patients.
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tations for more severe cases, are the only treatments available for HT1
patients [18,19]. Although the efﬁcacy of this drug improves greatly the
lifestyle of patients, late complications can persist. Moreover recent
data described the occurrence of HCC in some HT1 subjects, even
under NTBC therapy [19–22]. In this regard, many efforts have been
made in understanding the origin of damages occurring in HT1, but
the cellularmechanisms underlying the progression of this pathological
condition are not fully understood. When FAH-deﬁcient mice are treat-
ed with NTBC, they avoid early lethality; however, a high percentage of
NTBC-treatedmice develop hepatocellular dysplasia after 7months and
13–20% develop liver cancer after 18–24 months even when using a
regimented therapy (i.e. a higher NTBCdose of 4mg/kg/day plus dietary
tyrosine restriction) [23,24]. Arising evidences from this murine model
suggest an importantmetabolic impairment in FAH-deﬁcient livers due
to toxicity of the tyrosine-derived compounds.
In the present study, the fah knockoutmousemodel (fah−/−mouse)
was used in order to investigate themolecular pathways involved in the
development and progression of HT1 pathogenesis. By a slight protocol
modiﬁcation, we were able to extend the survival of fah−/− mouse in
absence of NTBC treatment from 5 to 15 weeks, therefore enabling the
study of HT1 progression on a longer period than previous studies and
most importantly until the appearance of neoplastic damages. Here
we report a stepwise activation of stress response pathways induced
by FAH impairment. The ﬁrst changes were observed within the ﬁrst
week of NTBC withdrawal as soon as the inhibitory action of the drug
becomes less effective, while the second phase appeared 4 weeks after
NTBC interruption and was accompanied by AFP up-regulation. Protein
expression patterns revealed an important crosslink among survival
mechanisms in chronic liver dysfunction. To corroborate these results,
we performed microarray proﬁling in mouse livers subjected to long-
term NTBC withdrawal. Analysis of microarray data showed an altered
expression of gene transcripts associated with differentiated hepaticfunctions and cell proliferation that occurred as a result of the chronic
damage induced by HT1 stress. The most affected pathways include
those involved in oxidative stress and detoxiﬁcation, inﬂammation-
cytokine-chemokine systems, hepatic ﬁbrosis and cellular growth.
Moreover, different transcripts associated with cancer progression
were found to be highly up-regulated in this stage.
2. Material and methods
2.1. Animals
Fourmonths-old fah knockout (fahΔexon5, referred to here as fah−/−)
malemicewere used asmodel for humanHT1 [25]. All animalswere fed
with a standard rodent chow (Charles River Rodent, Purina 5075-U.S,
Agribrands St.Hubert, QC, Canada) containing 0.51% tyrosine and
0.82% phenylalanine, and housed in a controlled environment with
12 h light–dark cycles. Pregnant females and pups fah−/−were treated
with 2-(2-nitro-4-(triﬂuoromethyl)benzoyl)cyclohexane-1,3-dione
(NTBC) in drinking water (7.5 mg/L, pH 7–7.3) until beginning of
experimentation. NTBC was generously provided by S. Lindstedt
(Gothenburg University, Sweden).
2.2. Treatment
To induce theHT1 phenotype, 4months-old fah−/−micewerewith-
drawn from NTBC therapy for periods of three days to 15 weeks. Mice
were weighted three times per week and periodically examined for
signs of clinical illness. At the end of each starvation period, three to
tenmicewere euthanized by an overdose of ketamine-xylazine cocktail
(2–3 times the anesthetic dose) followed by cervical dislocation. Fah−/−
mice receiving NTBC ad libitum (n = 5) were used as healthy control.
Fragments of harvested livers were processed for histology and the re-
maining tissues were snap-frozen in liquid nitrogen and stored at
−80 °C until analysis. All procedures for animal use were approved by
the local animal care comity (CPA-UL) according to the Canadian Coun-
cil on Animal Care (CCAC) recommendations.
2.3. Histological analysis
Mouse liverswere dissected, examined for gross features,ﬁxed in 4%
PBS-buffered paraformaldehyde, pH 7.4, and kept at 4 °C. Tissue sam-
pleswere embedded in parafﬁn-wax at 58 °C. Fourmicrometer sections
were prepared and stained with hematoxylin-eosin-saffron (HES),
Sirius Red for demonstration of ﬁbrosis and reticulin stain for analysis
of liver architecture. Immunohistochemistry was performed on
deparafﬁnized tissue sections with an anti-cleaved caspase-3 antibody
(rabbit polyclonal antibody, Cell Signaling, Danvers, MA) for demon-
stration of apoptosis and with an anti-glutamine synthetase antibody
(mouse monoclonal antibody clone 6, BD Biosciences, San Jose, CA) for
analysis of liver zonation; an indirect immunoperoxidase technique
performed according to the streptavidin-biotin method was used. All
techniques were performed at ANIpath, a university platform for exper-
imental animal histopathology (Lyon, France). Analysis and interpreta-
tion were done by a pathologist experienced in both human and
experimental liver pathologies (JYS). Diagnosis and classiﬁcation of
liver changes were performed according to international recommenda-
tions [26].
2.4. Immunoblotting
For Western blot analysis frozen livers were homogenized with a
teﬂon-glass pestle at 10% (W/V) in RIPA Buffer (20 mM Tris–HCl,
pH 7.5; 150mMNaCl; 1mMNa2EDTA; 1mMEGTA; 1%NP-40)with pro-
tease inhibitor cocktail tablets (cOmplete, Mini, EDTA-free; Roche Diag-
nostics, Indianapolis, USA) and phosphatase inhibitor cocktail tablets
(PhosSTOP; Roche Diagnostics, Indianapolis, USA). The homogenized
2605F. Angileri et al. / Biochimica et Biophysica Acta 1852 (2015) 2603–2617extracts were centrifuged at 10,000 g for 15 min at 4 °C. Protein concen-
trationwasmeasuredwith the Bio-Rad Protein Assay (Bio-Rad Laborato-
ries Inc., Hercules, CA). Proteins were resolved by electrophoresis on a
12% SDS-PAGE gel, transferred onto a nitrocellulose blotting membrane
(BioTrace NT, Pall Life Sciences), blocked with 5% non-fat dried milk in
TBS (Tris-buffered saline; 50 mM Tris, 150 mM NaCl, pH 7.5) and incu-
bated overnight at 4 °Cwith primary antibodies following recommenda-
tions by the manufacturers. Antibodies against Nrf2 (1:1000; #12,721),
CHOP (1:1000; #2895), Bcl2 (1:1000; #2870), phospho-Bad (Ser112)
(1:2000; #9296), phospho-Bad (Ser136) (1:1000; #5286), Mcl-1
(1:1000; #5453), Erk1/2 (1:1000; #4695), phospho-ERK1/2 (Thr202/
Tyr204) (1:1000; #4370), MEK1/2 (1:1000; #9122), phospho-MEK1/2
(Ser217/221) (1:1000; #9121), phospho-PKC (pan, γThr514) (1:1000;
#9379) were from Cell Signaling Technology (Danvers, MA, USA). Anti-
body against AFP (1:10,000) was a gift from Dr. L. Bélanger (CRCHUQ,
QC, Canada). HO-1 antibody (1:10,000; #ab13248)was fromAbcam(To-
ronto, ON, Canada). Phospho-eIF2α (Ser51) (1:1000; #KAP-CP130) was
purchased from Stressgen (Victoria, BC, Canada). Antibodies for BAX
(1:1000; #RB-063-P0) (NeoMarkers, Fremont, CA, USA) and PKC (pan)
(1:1000; #SAB4502356) (Sigma-Aldrich Canada Co., Oakville, ON,
Canada) were also used. Goat anti-mouse IgG or goat anti-rabbit IgG
peroxidase-conjugated (1:5000; #115–035–146 and #111–035–144 re-
spectively) (Jackson ImmunoResearch Lab, West Grove, PA, USA) were
used as secondary antibodies. Since commonly used reference proteins
(e.g. β-actin; α-,β-,γ-tubulin) were differently modulated in HT1 mice,
we selected the stably expressed HSP60 as loading control (1:10,000;
#37) [27]. Signals were revealed with Clarity™Western ECL Substrate
(Bio-Rad, Hercules, CA, USA) using the Odyssey® Infrared Imaging Sys-
tem (Li-COR, Biosciences, Lincoln, NE, USA). Densitometric analysis on
Western blot bands was performed using ImageJ 1.47v software. Values
were normalized to loading control levels and ﬁnally compared to the
fah−/− healthy control (NTBC-treated). Data in histograms indicate the
average of four mice for each time point, with error bars indicating
standard deviation.
2.5. RNA isolation
Total RNA was obtained from snap-frozen liver tissues using
mirVana™ PARIS™ Kit (Life Technologies, Burlington, ON, Canada) ac-
cording to the manufacturer's instructions. Puriﬁed total RNAwas elut-
ed in RNase-Free water followed by DNase-I digestion using the RNase-
free DNase kit and RNeasy spin column (QIAGEN, Mississauga, ON). The
quality and purity of RNA samples were checked by capillary electro-
phoresis using the Agilent 2100 Bioanalyzer and Agilent RNA Nano
6000 LabChip kits (Agilent Technologies, Santa Clara, CA, USA).
2.6. Gene expression analysis
To analyze gene expression proﬁle of fah−/− mice during chronic
liver injury, equivalent amounts of total RNA from four mice
discontinued from therapy for 7–8 weeks was pooled and ampliﬁed
using the two colors Agilent Low Input Quick Amp Labeling kit protocol.
A pool of fah−/− healthy control mice (n = 3) was used as normaliza-
tion control. Starting with 200 ng of total RNA, cyanine (Cy)3- or Cy5-
labeled cRNA was produced according to the manufacturer's protocol.
For each two-color comparison, 750 ng each of Cy3- and Cy5-labeled
cRNAwasmixed and fragmented using the Agilent In Situ Hybridization
Kit protocol (Agilent Technologies, Santa Clara, CA, USA). Hybridizations
were carried out with the Agilent Two-Color Microarray-based gene
expression platform using the 4 × 44K Two Colors Mouse Whole
Genome Microarray, 41,534 genes (Agilent Technologies, Santa Clara,
CA, USA). Two hybridizations with ﬂuorescent dye reversal technique
(dye-swap) were performed for each RNA sample from each group.
Slides were washed as indicated in Agilent's protocol and scanned
using an Agilent DNA Microarray Scanner. The Cy3/Cy5 intensity data
were extracted using Agilent's Feature Extraction software (AgilentTechnologies, Santa Clara, CA, USA). Values of genes in fah−/− mice
(NTBCw/o) were normalized against control samples (NTBC). Tran-
scriptome analysis was performed using Agilent Genespring GX11 soft-
ware (FRSQ-Réseau Cancer Core Genome Facility, Hôtel-Dieu, Québec,
Canada).
2.7. Functional genomics analysis
The genes signature was further analyzed with Ingenuity Pathways
Analysis (IPA Ingenuity software, QIAGEN, Redwood City, CA, USA). A
fold change cutoff of 2-fold and p b 0.001 was set to identify genes
whose expression was considered to be signiﬁcantly regulated. Biologi-
cally relevant networkswere drawn from the lists of genes differentially
expressed in untreated (NTBCw/o) and treated fah−/−mice. Core anal-
ysis was processed using direct and indirect relationships for pathway
scoring (the complete list of deregulated genes is available upon
request).
2.8. Statistical analysis
Comparisons between different experimental groups were made
using one-way ANOVA with a Dunnett's post-hoc analyses (Prism).
Results are means ± standard deviation, p values ≤0.05 were consid-
ered statistically signiﬁcant. Statistical signiﬁcance is represented by
asterisks.
3. Results
3.1. The fah knockout mouse model as an approach to understand liver
dysfunction and hepatocarcinogenesis in HT1 patients
The fahΔexon5mouse strain (fah−/−mouse) [23,25] has already been
extensively used as a useful model of human HT1 [7,28,29]. This model
presents most of the phenotypic and biochemical manifestations of
human HT1 on an accelerated time scale [6,7,23,25]. However none of
the previous studies has investigated the effects of the long-term stress
activation after complete NTBC withdrawal, due to the high mortality
rate in the post therapy interruption. Indeed, the mean survival of
fah−/−mice following NTBC withdrawal is around 4 to 5 weeks, when
they die from liver failure accompanied by severe weight loss [7,8,30,
31]. We noticed that the high mortality rate observed was often associ-
ated with dehydration and intestinal problems (black stools and diges-
tive tract ﬁlling). Thus we modiﬁed the traditional protocol integrating
the mice diet from the fourth week post-withdrawal with a daily dose
of water-soaked grinded rodent's food in an attempt to alleviate these
complications (Fig. 2A). This simple change in food presentation result-
ed in an unexpected considerable increase of the mean survival time
(Fig. 2B), from 5 to more then 15 weeks after NTBC discontinuation.
The severe weight loss previously reported during the ﬁrst 5 weeks fol-
lowing NTBC removal was followed by a stabilization of the mean
weight and even an increase in weight up to 15 weeks (Fig. 2C). Each
time point was chosen as representative of different stages of HT1
stress. In mice, NTBC has a biphasic kinetic of elimination with an initial
phase having a half-life of 2.7 h and a subsequent phase having a half-
life of 54 h [32], which corresponds to the mean terminal plasma half-
life of NTBC in human (~54 h, DrugBank DB00348, http://www.
drugbank.ca/drugs/DB00348). While a small amount of NTBC persists
in the liver and kidneys up to seven days after a single dose, the com-
plete inhibition of HPPD activity was observed only in the three ﬁrst
days after NTBC uptake [32] suggesting that FAA, MAA and SA starts to
accumulate thereafter. We therefore chose three days of NTBC with-
drawal as the ﬁrst time point to start the evaluation of the early events
induced by HT1 toxic metabolites accumulation. Livers of fah−/−mice
kept on NTBC from birth until time of sacriﬁce, were used as control.
Gross inspection of all fah−/−mice under drug starvation revealed a
progressive variation in liver/body weight ratio (L/BW) (n = 3–10;
Fig. 2. Effect of NTBC withdrawal on mice weight and survival. (A) 15 weeks withdrawal protocol. Number of harvested mice per time point is indicated. Water soaked food treatment
starts after 4 weeks of NTBC interruption. (B) Effect of water soaked food was evaluated onmice survival. Mice supplemented with water soaked food (n= 7) exhibited signiﬁcantly in-
crease in survival time against mice under regular diet (n = 7). (C) Body weight curves (%) for male fah−/− mice. Mice fah−/− NTBC-treated ( ), and after NTBC-withdrawal ( ),
were weighed three times per week. Each point in the curves represents the average of at least three mice, with error bars indicating standard deviation. (D) Liver/body weight
ratio at different time point of fah−/− harvested mice. Results are means ± s.d. (n = 3–10) and are compared to the liver/body weight ratio of the control group (NTBC-treated);
*** p b 0.001 and **** p b 0.0001.
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Macroscopic appearance of livers in dissected mice was characterized
by several dysmorphic changes, including the appearance of multiple
nodules (Fig. 3). L/BW was up to 2.4-fold higher than normal after
15 weeks of drug starvation (n = 10; Figs. 2D and 3A,C). At the end
point of 15 weeks of withdrawal, 100% of surviving mice (n = 10) re-
vealed the presence of liver nodules. This long-range protocol permitted
us to explore into more depth HT1-associated liver dysfunction and the
process leading to neoplastic lesions that could eventually develop into
HCC.
3.2. NTBC withdrawal induces acute liver failure with histologically evident
hepatocellular changes
Histological examination showed that mild hepatocellular changes
were present in fah−/− treated mice: hepatocytes were enlarged and
presented very large, round nuclei containing several large nucleoli;
many hepatocytes showed micro- and even macro-vesicular steatosis;
there were no architectural changes and no ﬁbrosis (Fig. 4A). The pres-
ence of such changes before therapy interruption suggests that NTBC
treatment is not able to cover all damages induced by toxic metabolites
accumulation, as previously reported [33,34]. Of note, MAA and FAA are
highly reactive and considered as the primary causes of hepatocytes
damage observed in HT1 [1,10,35,36]. After NTBC discontinuation, se-
vere liver lesions, combining hepatocellular changes, inﬂammation
and ﬁbrosis were observed (Fig. 4B, C). Hepatocellular plates were dis-
organized, irregular and thickened. Hepatocytes were enlarged andshowed ballooning along with micro- and macro-vesicular steatosis;
dysmorphic nuclei were present (Fig. 4B). Small inﬂammatory aggre-
gates were scattered within liver lobules and proliferation of oval-like
cells was observed mainly in the periportal areas of hepatic lobules.
Oval-like cells were arranged in cohesive sheets or in pseudoglandular
structures and were morphologically similar to the oval cells described
at the initiation of the process of chemical carcinogenesis (Fig. 4B).
Periportal and perisinusoidal ﬁbrosis was present. Sirius Red staining
of liver sections conﬁrmed the presence of thin ﬁbrotic septa extending
from slightly enlarged portal tracts and running along preexistent sinu-
soids (Fig. 4C panel a). Finally, apoptotic ﬁgureswere frequent andwere
highlighted by the immunohistochemical detection of cleaved caspase-
3 (Fig. 4C panel b).
After 15 weeks of therapy interruption, the livers of fah−/− mice
usually contained several nodules (Fig. 3C). Some nodules displayed
features reminiscent of those presented by regenerative macro-
nodules in human diseased liver: they contained ﬁbrous septa running
between normal hepatocyte plates. Other nodules were large and well
demarcated (Fig. 5A). They showed the histological features of liver
cell adenoma. They were formed by thickened hepatocellular plates,
retaining a regular disposition (Fig. 5B) but devoid of the reticulin
network associated with hepatocellular plates in the normal liver;
only rare and dispersed reticulin ﬁbers were present (Fig. 5C). No
portal tract was visible. Large vessels were seen running through the
tumor tissue. Tumor cells were monomorphic and characterized by
increased nucleo-cytoplasmic ratio and basophilic cytoplasm; there
was no signiﬁcant cell atypia and only rare mitoses were observed
Fig. 3. Representative pictures of whole livers from fah−/−mice followingNTBC discontinuation. (A) Macroscopic appearance of harvested livers at different time point of 15 weeks with-
drawal protocol. Scale bars, 1 cm. (B) Cirrhotic features of liver harvested at 8 weeks post withdrawal. (C) Macronodular appearance of liver harvested at 15 weeks post therapy
discontinuation.
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restricted to the few rows of hepatocytes immediately surrounding
centrilobular veins, was undetectable in adenoma tissue; its expression
was retained in the adjacent peritumoral tissue but its distribution
was modiﬁed, likely as a result of the architectural disturbances
associated with liver injury (Fig. 6). Between liver cell adenomas, the
hepatic parenchyma showed major histological changes, as described
above, including marked hepatocellular lesions and extensive
perisinusoidal ﬁbrosis as shown by Sirius Red and reticulin stains
(Fig. 5C).
3.3. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is induced in the ear-
ly phase of NTBC withdrawal
Endogenous oxidative stress enhanced by accumulation of metabo-
lites such as FAA has previously been reported in several studies [10,
12,14]. It has been observed that FAA causes Golgi apparatus disruptionand elicit stress defensive mechanisms by depleting cells of GSH [5,6,
10]. It has been suggested that, Nrf2 could be a critical modulator of
FAA-induced toxicity, modulating survival of stressed hepatocytes and
delaying tumor development [28]. Thus we examined the levels of
Nrf2 protein during the NTBC withdrawal protocol in HT1 stressed
mice. The level of Nrf2 was measured on fah−/−mice after short-term
(from 3 days to 1 week) and long-term (from 4 to 15 weeks) therapy
discontinuation (n = 3–10; Fig. 2). Expression of Nrf2 occurred
soon after NTBC interruption (Fig. 7A,C), with a peak of expression
in the acute phase of the tyrosinemic stress (e.g. ﬁrst week post
withdrawal). However an Nrf2 decrease was observed during the HT1
progression. As shown by Western blot analysis (Fig. 7A,C) after four
weeks of therapy discontinuation, Nrf2 levels were lower than after
one week post-withdrawal, and this trend became more evident after
longer therapy interruption (e.g. 8 to 15 weeks after NTBC removal),
when liver homogenates presented almost undetectable levels of this
protein.
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Nrf2 has been reported to regulate the expression of many
cytoprotective enzymes in response to oxidative stress through bindingof antioxidant responsive element (ARE) [37–41]. Among transcription-
al targets of Nrf2, heme oxigenase-1 (HO-1)has been the object ofmany
investigations for its multiple roles in molecular signaling. Past studies
on the same murine model of HT1, showed an increase of this protein
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weeks [6]. This increasewas associated to cell stress induced by retrieval
fromNTBC treatment andwas suggested to be part of ER stress response
promoted by FAA oxidative damage. Thus we examined HO-1 levels in
liver homogenates of fah−/−mice following a longer NTBC discontinua-
tion. As observed the expression of HO-1 proteinwas induced in a time-
dependent manner (Fig. 7A,C). Indeed, HO-1 expression was almost
absent in NTBC treated fah−/− mice but was induced in all the NTBC-
withdrawn groups. In particular, the maximal induction of HO-1 was
observed after four weeks of therapy discontinuation. In animals with-
drawn for longer period (n = 4–10) these levels were maintained
throughout the entire starvation time even during neoplastic transfor-
mation (Figs. 3 and 7A,C). These results conﬁrm and extend our
previous observations in the ﬁveweekswithdrawalmodel [6].Whether
this is regulated by translocation of Nrf2 in the nucleus or by other
mechanisms has not been measured here. It would certainly be
interesting as future perspective to investigate more in details whether
HO-1 induction relies or not on Nrf2 nuclear migration during HT1
progression.
3.5. Induction of eukaryotic translation initiation factor 2α eIF2α and C/EBP
homologous protein-10 (CHOP) in response to NTBC withdrawal
Previous in vitro and in vivo studies during the ﬁrst ﬁve weeks of
NTBC withdrawal showed an activation of eIF2α as consequence of
the oxidative stress elicited by toxic metabolites accumulation in cells
lacking FAH activity [6]. Since phosphorylation of the α subunit of
eIF2 at serine 51 (p-eIF2α) is a master regulator of cell adaptation to
various forms of stress with implications in cancer growth and prolifer-
ation, we then asked whether p-eIF2α could contribute in sustaining
oxidative stress pathways in the HT1 late neoplastic process. As
shown in Fig. 7B,D, p-eIF2α was already induced in mice after
ﬁve days from NTBC interruption. Moreover, analysis of livers from
mice subjected to a longer interruption demonstrated that, p-eIF2α re-
mains persistently high all through therapy discontinuation (Fig. 7B,D),
suggesting an important role for this factor in managing chronic liver
injury.
A major target gene of p-eIF2α is the transcription factor CHOP,
which is often up-regulated under stress conditions. Bergeron et al. re-
ported a gain of CHOP protein expression in fah−/−mice already after
the ﬁrst week of NTBC withdrawal [6]. Here, Western blot analysis
shows a light increase in CHOP expression at four weeks post-
withdrawal, with a stronger induction observed in the late stages of
HT1 stress when neoplastic lesions are observed (Figs. 3 and 7B,D).
3.6. Sustained liver injury leads to impairment of mitochondrial pathways
with progressive cell death resistance
Cell death resistance has been reported to occur rapidly and to affect
the majority of hepatocytes in the murine model of HT1 [7,29] but only
limited information exists on apoptosis modulation during late HT1
progression. Therefore we investigated the modulation of the BCL-2
family members to better understand how the mitochondrial apoptotic
pathways may inﬂuence the survival status in liver presenting neoplas-
tic lesions (e.g. 8 to 15 weeks post therapy interruption). As previouslyFig. 4.Histopathological evaluation of postwithdrawal liver damage in fah−/−mice. Panels are r
each series. Liver lesions observed in 4 months-old fah−/−mice treated with NTBC (A) or remo
patocellular changes: hepatocytes are enlarged and often contain micro- or macro-vesicular ste
×350. (B) fah−/−micewithdrawn fromNTBC treatment present severe hepatocellular changes
morphic nuclei are visible (N) and oval-like cell proliferation is marked. Oval-like cells, identiﬁ
plasm, are arranged in small sheets or in tubular structures (black arrows). Inﬂammatory
cytoplasm, are present (large open arrows). HES staining, ×250. b: At highermagniﬁcation, the
are frequent (large open arrows). HES staining, ×320. (C) Fibrosis and apoptosis in fah−/−mi
connective septa running between disorganized hepatocyte plates and extending from portal t
tection of cleaved caspase-3. Several positive cells are visible (arrows). Indirect immunoperoxireported [7,8], NTBC withdrawal resulted in approximately 30-fold in-
duction of Bcl-2 protein already in the 5th day post withdrawal,
conﬁrming an activation of survival mechanisms during the early HT1
stage (Fig. 8). Bcl-2 levels remained high at 1 and 4 weeks of NTBC dis-
continuation and returned to normal following longer discontinuation.
Moreover, HT1 progression resulted in a sequential increase of phos-
phorylation levels of Bad, a pro-apoptotic Bcl-2 family member
(Fig. 8). Indeed, phosphorylation of Bad appears on S136, ﬁve days
after therapy discontinuation, while phosphorylation on S112 three
weeks later with a peak registered at 8 weeks post-withdrawal
(Fig. 8). Phosphorylation at either site should result in loss of the ability
of Bad to form hetero-dimer with the survival proteins Bcl-XL or Bcl-2
eliciting the reinforcement of the pro-survival potential and impairing
its apoptogenic functions [42]. Contrary to Bcl-2 which is involved in
the early stage of HT1, Mcl-1, another pro-survival member of the Bcl-
2 family,was induced at 4weeks of NTBCwithdrawal and later, presum-
ably compensating the decreased expression registered for Bcl-2 pro-
tein (Fig. 8). Numerous, diverse cell-types have been shown to rely on
Mcl-1 for their survival and development [43]. Furthermore Mcl-1 has
been reported to block the progression of apoptosis by binding and se-
questering the pro-apoptotic proteins Bcl-2-associated protein X (Bax)
[43], capable of forming pores in the mitochondrial membrane. Levels
of Bax were therefore measured by Western blot analysis and, as
shown in Fig. 8, Bax was highly deregulated soon after therapy discon-
tinuation with a marked diminution in the long-term withdrawal.3.7. Activation of MAPK cascade upon HT1 stress
To further explore the signaling events responsible for death resis-
tance duringHT1progression,we investigated other pathways often ac-
tivated in cancer cells exposed to chronic stress. Protein kinase B, better
known as Akt, was already reported to contribute in apoptosis resis-
tance during HT1 stress [7]; however our new data and others results
are indicative of a more complex deregulation involving the coopera-
tion of many others cellular mechanisms. Since, extracellular signal-
regulated protein kinase (ERK1/2), a member of the mitogen-
activated protein kinase (MAPK) family crucial for regulating cell
growth and differentiation in stress condition, is often aberrantly
expressed in oncogenesis and since alteration in ERK1/2 activity has
been reported in FAA-treated cells [5], we examined expression levels
of this protein in fah−/− mice subjected to an increasing tyrosinemic
stress (i.e. short- and long-term NTBC withdrawal). ERK1/2 activation
was assessed using an antibody against the active form, i.e. against
phosphorylated ERK1/2 (p-ERK1/2). As shown in Fig. 9, ERK1/2was sig-
niﬁcantly activated after four weeks of NTBC removal. No signiﬁcant
variation in total ERK1/2 protein level was observed (Fig. 9A). Levels
of mitogen-activated protein kinase kinase (MEK1/2) were then inves-
tigated, as it is one of the upstream mediators of ERK1/2 activation in
theMAPK pathway. As observed inWestern blot analysis, NTBC remov-
al resulted in an increase in phosphorylatedMEK1/2 (p-MEK1/2) levels
(Fig. 9) at 4 and 8 weeks after therapy interruption, suggesting the in-
volvement of Ras/MEK cascade in ERK1/2 phosphorylation in late
events of HT1 progression. Total levels of MEK1/2 protein were not sig-
niﬁcantly changed trough all the HT1 process.epresentative of at least three pictures taken per sample of a total number of n=4mice for
ved from NTBC therapy during 15 weeks (B, C). (A) fah−/− treated mice present mild he-
atosis, they show large dysmorphic nuclei with several well formed nucleoli. HES staining,
. a: Enlarged hepatocytes frequently containmicro- or macro-vacuoles of steatosis (*), dys-
able to their large nucleus containing dispersed chromatin and to their well visible cyto-
aggregates, made of loosely grouped small lymphoid cells with dark nuclei and scant
structures made by oval-like cells are well visible (dark arrows); inﬂammatory aggregates
ce withdrawn from NTBC treatment. a: Sirius Red staining highlights the presence of thin
racts (PT). CV: centrilobular vein. Sirius Red staining, ×170. b: Immunohistochemical de-
dase technique, ×240.
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Fig. 6.Glutamine synthetase distribution is altered followingNTBCwithdrawal. Glutamine
synthetase (GS) immunodetection in normal mouse liver (A), diseased liver from 4
months-old fah−/− mouse withdrawn from NTBC during 15 weeks (B), and in a liver
cell adenoma (C). A) In the normal liver, GS is restricted to the few rows of hepatocytes
surrounding centrilobular veins (CV) (×190). B) In diseased liver, GS expression is
retained but the distribution is markedly enlarged and disorganized (×190). C) In liver
cell adenoma (T), no expression is detectable in contrast to adjacent peritumoral liver
(NT) (×110). PT: portal tract.
2611F. Angileri et al. / Biochimica et Biophysica Acta 1852 (2015) 2603–26173.8. Protein kinase C (PKC) is recruited during oxidative damage in HT1
stress reinforcing cell survival and sustaining neoplastic lesions progression
Induction of the MAPK cascade can be carried out through the acti-
vation of PKC, a family of speciﬁc serine-/threonine-kinases implicated
in a wide variety of cellular responses, including proliferation and regu-
lation of gene expression [44–46]. Moreover during oxidative stress, the
PKC family has been proposed to play an important role in the Ca2+me-
diated signaling of apoptosis by interactionwith pro- and anti-apoptotic
members of the Bcl-2 family [44,47,48]. Thus, considering our previous
observations on Ca2+ release in FAA–treated cells [5], and taking into
account the results obtained on MAPK cascade and apoptosis signaling,
we next assessed the status of the PKC survival pathways considering
that it may constitute one of the central nodes in HT1 progression.
PKCs levels and its active phosphorylated forms were measured in
liver homogenates of mice after different periods of NTBC withdrawal.
Interruption of therapy resulted in a progressive induction of PKC iso-
forms up to 15 weeks (Fig. 10). Immunoblotting results also showed
an uneven modulation of total PKC and phosphorylated PKC isoforms
levels in the different stages of drug withdrawal (Fig. 10B). This result
may indicate that preferential phosphorylation of some isoforms may
occur in the development and progression of the HT1 liver pathology.
3.9. Transcriptomic analysis in liver of fah−/−mice under long term NTBC
withdrawal reveals cluster of genes involved in cancer progression
Liver injury in bothHT1-affectedmice andHT1 patients has been as-
sociated with alteration of transcripts related to oxidative stress, detox-
iﬁcation enzymes and GSH–metabolism related proteins [14,28,33]. In
order to identify genes involved in the chronic stress induced during
HT1, we performed microarray proﬁling in mice after 7–8 weeks of
drug starvation, (n = 4), using fah−/− NTBC-treated mice as control
(n = 4). This time point was characterized by signiﬁcant modulation
of many signaling cascades (Figs. 7-10) and appearance of neoplastic
changes (Figs. 3-6).
Interestingly, 32 genes related to GSH metabolism and oxidative
stress were up-regulated following 8 weeks of NTBC discontinuation,
reﬂecting a strong transcriptional response to oxidative stress in the
progression of the chronic HT1 stage (Table 1). In accordance with im-
munoblotting experiments (Fig. 7A, C), HO-1 transcript (HMOX) was
up-regulated bymore than 5 fold (Table 1). Further integration of differ-
ently regulated genes into speciﬁc regulatory signaling networks was
carried out using Ingenuity Pathway Analysis (Fig. 11A). According to
these data, we clustered among over 3000 genes differently regulated.
The most signiﬁcant enriched biological processes and networks were
those involved in cellular growth and proliferation, cell survival, inﬂam-
matory response, hepatic ﬁbrosis and hepatic stellate cells (HSCs) acti-
vation, organismal injury and cancer (Fig. 11A).
Throughout the top overexpressedmolecules we found genes wide-
ly correlated in literature with the oncogenic process (Fig. 11B). Among
these, alpha-fetoprotein (AFP), one of the most widely used biomarker
for HCC surveillance [49], was also tested by Western blot analysis,
showing up to 35-fold higher expression in long-termNTBCwithdrawal
(Fig. 12).
4. Discussion
Chronic liver injury inﬂicted by HT1 has been associated with the
highest risk of HCC of any human disease [29,50]. Although NTBCFig. 5. Presence of liver cell adenoma in fah−/−micewithdrawn fromNTBCduring 15weeks. Pan
mice for each series. (A) Low magniﬁcation of a liver cell adenoma presenting as a well-dema
magniﬁcations of the periphery (a) and center (b) of a liver cell adenoma; the histological app
(NT). Tumor cells are monomorphic, with an increased nucleo-cytoplasmic ratio and a basophi
tosis; portal tracts (PT) are visible only in the adjacent liver; only venous structures (V) are prese
shows the scarcity of reticulin network in liver cell adenoma tissue (T) as contrast to adjacent no
within adenoma tissue; the reticulin network is poor and highly disorganized. Reticulin stainintherapy has improved the expectancy of life in HT1 patients since its in-
troduction in 1992 [51–53], the risk of developing HCC is still a serious
threat for improving the management of this devastating disease.
Histological evidences shows that fah−/−mice, continuously under
therapy since mother pregnancy, experience signs of stress under
basal conditions, suggesting that NTBC treatment does not fully normal-
ize HT1-induced alterations as already suggested by others [24,33]. This
may indicate that HPPD has some remaining activity even under NTBC
treatment and that although the drug reduces FAA, MAA and SA accu-
mulation, their production may not be completely suppressed. As con-
sequence a subtle and continuous damage induced by these toxic
metabolites could expose HT1 patients to the risk of developing HCC
as long-term complication. In the mouse model, the severity of this
pathological condition is evident soon after fah−/− mice are removed
from therapy, when they start to manifest a progressive degradation
of the normal physiology. Up to now the rapidly lethal phenotype
induced bydrugwithdrawal in the fah−/−mice represented a limitation
for long-term observation of the HT1 progression, since the median
mice survival was between four and ﬁve weeks after therapy interrup-
tion (Fig. 2B). Herein, we modiﬁed our experimental protocol
supplementing the mice diet with water soaked food to overcome the
dehydration and gastro-intestinal problems that characterize the acute
HT1 phenotype in fah−/−mice. This expedient resulted in a longer sur-
vival of mice under experimental protocol allowing an extension of our
observations up to 15 weeks post drug removal. Histological analysisels are representative of at least three pictures taken per sample of a total number of n=4
rcated, expansive nodule (T, tumor, NT, non tumoral liver). HES staining, ×150. (B) High
earance of the adenoma (T) is very different from that of the adjacent peritumoral tissue
lic cytoplasm. They are arranged into thick plates; there is no cell atypia and no visible mi-
ntwithin the tumor tissue. HES staining, ×220. (C) At lowmagniﬁcation (a), reticulin stain
n tumoral liver (NT). At highermagniﬁcation (b), only scattered reticulin ﬁbers are visible
g, ×220.
Fig. 7. Effect of NTBC withdrawal on ER stress response proteins. Protein expression levels of Nrf2 (A), HO-1 (A), p-eIF2α (B) and CHOP (B) following NTBC interruption. One mouse is
presented per group. (C, D) Bar graphs showing quantiﬁcation of the expression level of each protein compared with the expression levels of the control group (NTBC-treated) and
normalized to the loading control (HSP60). Data are expressed as means ± s.d. (n = 4). Western blots are representative of at least four independent experiments. * p b 0.05,
** p b 0.01, *** p b 0.001 and **** p b 0.0001.
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interruption, showed a progressive and constant liver degeneration,
under drug starvation, accompanied by activation of stress and survival
pathways with neoplastic lesions in 100% mice under experimentation.
Altogether, the immunoblotting experiments suggest that HT1 progres-
sion can be divided in two-phases. It was already shown that the half-
life of NTBC in mouse plasma is 54 h and that HPPD is completely
inhibited only in the 3 ﬁrst days following a single-dose of NTBC [32].
However it was also shown that a small portion of NTBC is retained in
the liver up to 7 days after NTBC uptake, preventing the full recovery
of HPPD activity before the ﬁrst week post-withdrawal [32]. Therefore,
the differences observed between the early and late events of HT1
may be in part linked to a different level of HT1-toxic metabolites accu-
mulation. Furthermore, immunoblotting results revealed the involve-
ment of ER key factors such as Nrf2 and eIF2α since the early stage of
HT1-induced oxidative damage.
Nrf2 can be activated by different mechanisms such as oxidation of
its sequestering partner kelch-like ECH-associated protein 1 (Keap1)
or directly by PERK [54]. Another not yet tested possibility could be by
the direct interaction of FAA with sulfhydryl groups of Keap1 since
Nrf2 levels increased immediately after NTBC withdrawal in liver ho-
mogenates of fah−/−mice. However, Nrf2 levels decrease in the long-
term therapy interruption. Since Nrf2 has been shown to play a crucialrole in preventing liver ﬁbrosis [28,55] andNrf2−/−micewere reported
to suffer an abnormality in lipid metabolism [56,57], the decreased
expression of this transcription factor in fah−/−mice might then be as-
sociated with an impairment of hepatic regeneration and lipid homeo-
stasis in the advanced stage of HT1 disease.
Analyses on fah−/−mice revealed that NTBC discontinuation elicits
signiﬁcant eIF2α activation soon after drug interruption. EIF2α phos-
phorylation is known to attenuate global protein synthesis and ER over-
load by misfolded proteins, which lowers energy expenditure and
facilitates reprogramming of gene expression to remediate stress dam-
age [58,59]. For example, increased p-eIF2α mediates expression of
genes involved in adaptation to amino acid starvation and alleviation
of oxidative damage from nutrient deprivation [60,61]. It is possible
that stressed hepatocytes use the anti-oxidant function of p-eIF2α for
inducing transcription of genes involved in the import of thiol-
containing amino acids and glutathione biosynthesis, as means to
counteract the continuous oxidative insults elicited by FAA and MAA
overproduction. Moreover, p-eIF2αwas suggested to increase the acti-
vation of CHOP in condition of cellular damage coupled with metabolic
stress [62].
In the fah−/−model, CHOP was induced from the eighth week post
therapy interruption. CHOP is a stress-regulated transcription factor
that inﬂuences ER function and cell viability through its actions on
Fig. 8.Mitochondrial apoptotic pathway duringHT1 progression. (A) Immunoblot analysis showingmitochondrial proteins of the apoptotic pathway from a representativemouse for each
group (n = 4). Phosphorylation is indicative of a loss of function in analyzed proteins. (B) Bar graphs showing quantiﬁcation of the expression level of each protein compared with the
expression levels of the control group (NTBC-treated) and normalized to the loading control (HSP60). Data are expressed as means ± s.d. (n = 4). Western blots are representative of
four independent experiments of a total number of n = 4 mice for each series. * p b 0.05, ** p b 0.01, *** p b 0.001 and **** p b 0.0001.
2613F. Angileri et al. / Biochimica et Biophysica Acta 1852 (2015) 2603–2617target genes involved in protein synthesis and oxidative protein folding
[63,64]. While it is known to mediate apoptosis in response to ER stress
and is considered as a sentinel for the failure of cells to adapt to chronic
stress [65–68], several studies hint at an oncogenic role of CHOP in cer-
tain tumor environments [69–71]. Indeed, CHOP was hypothesized to
contribute to the pathogenesis of HCC in vivo by promoting apoptosis,
inﬂammation, ﬁbrosis and compensatory proliferation [72]. Therefore,
activation of CHOP in the late stage of HT1 hepatic dysfunction could
worsen the inﬂammatory response and stimulates HSCs activation
and ﬁbrosis, enhancing compensatory hepatocyte proliferation and sus-
taining liver tumorigenesis.
In such context of multifaceted interactions addressed to counteract
an overall imbalance of the homeostatic equilibrium, cellular defense
mechanisms orchestrate the execution of the antioxidant responseFig. 9.MEK/ERK protein expression level in fah−/−withdrawnmice. (A) Immunoblot analysis
endogenous total level were analyzed to evaluate level of activation of each protein. (B) Bar grap
the expression levels of the control group (NTBC-treated) and normalized to the loading contro
ERK1/2 did not show any signiﬁcant variation and are therefore not shown. Western blots are
series. *** p b 0.001 and **** p b 0.0001.element-dependent gene transcription program. The complexity of
HO-1 regulation is illustrated by the multiplicity of signaling cascades
that are involved in the regulation of this gene, including PKCs and
MAPKs [73], and that are highly represented in HT1 progression.
Many recent evidences suggest a role for HO-1 in promoting cancer,
since its activity has closely been related to growth, apoptosis, angio-
genesis, invasiveness, and metastasis of solid tumors [74,75]. Previous
results already reported its involvement in liver injury induced by HT1
stress, however its role was not investigated as part of the pathways
involved in liver tumorigenesis [6]. Here, the high protein levels of
this factor found in the late HT1 stage (Fig. 7A,C), might indicate
that it plays a crucial role not just in defense against oxidative stress
induced by HT1 toxic metabolites but also in promoting survival of pro-
liferating cells. Moreover, HO-1 induction results in production ofshow data from a representative mouse for each group (n = 4). Phosphorylated form and
hs showing quantiﬁcation of the expression level of pMEK1/2 and pERK1/2 comparedwith
l (HSP60). Data are expressed asmeans± s.d. (n= 4). Levels of endogenousMEK1/2 and
representative of four independent experiments of a total number of n = 4 mice for each
Fig. 10. PKC expression levels in 15 weeks post withdrawal protocol. (A) Immunoblot analysis of phosphorylated forms of total PKC and endogenous PKC levels. Images show represen-
tative data from individual mouse in each group (n= 4). (B) Bar graphs showing quantiﬁcation of the expression level of each protein comparedwith the expression levels of the control
group (NTBC-treated) and normalized to the loading control (HSP60). Data are expressed asmeans± s.d. (n= 4).Western blots are representative of four independent experiments of a
total number of n = 4 mice for each series. *p b 0.05,**p b 0.01, ***p b 0.001 and ****p b 0.0001.
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phosphofructokinase-1 activity, a rate-limiting glycolytic enzyme. This
mechanism shifting glucose utilization from glycolysis toward the pen-
tose phosphate pathway would determine directional glucose utiliza-
tion to ensure resistance against oxidative stress for cancer cell
survival [76]. Increasing the intracellular use of glucose could then con-
tribute in decreasing blood sugar levels, a phenomenon observed in
HT1-affected individuals [19] and in animal models [7,77]. Most cancer
cells exhibit increased glycolysis and use this metabolic pathway for
generation of ATP as a main source of their energy supply. ThisTable 1
Top up-regulated genes involved in GSH metabolism and oxidative stress response in 8




ATF3 Activating transcription factor 3 4
CYGB Cytoglobin 2.56
DHCR24 24-Dehydrocholesterol reductase 2.7
ERO1L ERO1-like (S. cerevisiae) 3.773
G6PD2 Glucose-6-phosphate dehydrogenase 2 4.86
G6PDX Glucose-6-phosphate dehydrogenase X-linked 8.01
GCLC Glutamate-cysteine ligase, catalytic subunit 6.07
GGT1 Gamma-glutamyltransferase 1 10.52
GPX2 Glutathione peroxidase 2 9.28
GPX3 Glutathione peroxidase 3 3.241
GPX4 Glutathione peroxidase 4 2.327
GPX7 Glutathione peroxidase 7 3.4
GSR Mitochondrial glutathione reductase 4
GSTA1 Glutathione S-transferase, alpha 1 (Ya) 3.94
GSTA2 Glutathione S-transferase, alpha 2 (Ya) 2.74
GSTM2 Glutathione S-transferase, mu 2 5.408
HIF1A
Hypoxia inducible factor 1, alpha subunit (basic
helix-loop-helix transcription factor) 2.18
HMOX Heme oxygenase 1 5.98
HSF2 Heat shock factor 2 3.3
MGST2 Microsomal glutathione S-transferase 2 9.946
MGST3 Microsomal glutathione S-transferase 3 7.24
MMP14 Matrix metallopeptidase 14 (membrane-inserted) 3.34
NQO1 NAD(P)H dehydrogenase, quinone 1 5.85
PERK Eukaryotic translation initiation factor 2-alpha kinase 3 2.348
PGD Phosphogluconate dehydrogenase 3.34
PTGS2
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclooxygenase) 2.4
RRM2 Ribonucleotide reductase M2 2.87
RRM2B Ribonucleotide reductase M2 B (TP53 inducible) 2.7
SLC7A11 Solute carrier family 7, member 11 8.4
SRXN1 Sulﬁredoxin 1 4.482
TXNRD1 Thioredoxin reductase 1 2.324
UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 3.2phenomenon is known as the Warburg effect and is considered as one
of the most fundamental metabolic alterations during malignant trans-
formation. Biochemical and molecular studies suggest several possible
mechanisms by which this metabolic alterationmay evolve during can-
cer development. Thesemechanisms includemitochondrial defects and
malfunction. Mitochondria and ER interact physically and functionally
to form endomembrane networks that constitute a complex connection
in regulating several signaling mechanisms. The molecular foundations
of this crosstalk are diverse, and Ca2+ is one of the most important sig-
nals that these organelles use for communication [78]. Since distur-
bance of ER homeostasis in HT1 stress has been shown to result in
functional alterations of Golgi organelles andmobilization of intracellu-
lar Ca2+ reservoirs [5], it is possible that the observed impairment ofmi-
tochondrial pathways is a consequence of this perturbation. Indeed,
anti-apoptotic and pro-apoptotic members of the Bcl-2 family have
been shown to be ﬁne sensors of Ca2+ homeostasis controlling cell
death induced by agent known to trigger ER stress [79–81]. Here we
show that modulation of these pathways occurs not just in the initial
phase of HT1 stress, but instead mitochondrial dysfunction seems to
be also involved in the late stage when neoplastic lesions are observed.
The rise in intracellular Ca2+ level is furthermore linked to activation of
multiple signaling modulators critically regulated by Ca2+ conductance
like several PKC isoforms and MAPK/ERKs. Because of their key roles in
cell signaling, PKC isozymes have been the object of many studies as
potential therapeutic target for several diseases [82,83]. Substantial in-
formation obtained from animal models indicates that during cancer
cell proliferation, PKC isozymes stimulate survival or proliferation asso-
ciated signaling pathways, such as Ras/Raf/MEK/ERK or PI3K/Akt/mTOR
pathways, but suppress the expression of cancer suppressor-associated
or apoptotic signals such as caspase cascade or Bax subfamily [82]. Here
we show that hepatic damage following FAA/MAA/SA toxic actions re-
sults in an induction of PKC signalingpathway. Further studies are need-
ed to elucidate the involvement of the different PKC isozymes in HT1
dysfunction and to establish whether the mechanism of PKC activation
resides on direct Ca2+ mobilization or if it is more dependent on recep-
tor mediated pathways (i.e. tyrosine-kinase receptor, RTK and G-
protein-coupled receptor, GPCR). Nonetheless, it seems appropriate to
suggest that PKC is involved in HT1 progression and that through target
protein phosphorylation PKC isozymes, directly or indirectly, participate
in activation of several signaling cascade sustaining cancer development
in HT1 patients. Among the most recognized pathways downstream
PKC activation in cancer environment, an important role has been at-
tributed to MAPK/ERK signaling cascade [84,85]. RAS/RAF/MEK path-
way is activated in more than 30% of human cancers and ERK
phosphorylation has been associated with transcriptional mutagenesis
causing tumor development in mammalian cells [86,87]. Induction of
this pathway during the pathological progression of HT1 phenotype
Fig. 11. Gene expression analysis in fah−/−mice withdrawn from NTBC. Microarray analysis was performed on 4 mice withdrawn from NTBC for 7–8 weeks to identify gene involved in
HT1 progression. (A) Functional analysis of the top deregulated genes in liver, classiﬁed according to Ingenuity Pathway Analysis (IPA). P valueswere corrected for multiple testing by the
Benjamini–Hochberg method and calculated by IPA software. Values in parentheses indicate the number of genes in each category. (B) Top overexpressed genes related to cancer in lit-
erature. Values of fah−/− untreated mice were normalized to fah−/−mice under NTBC treatment (n= 4). Data are expressed asmean of two experiences in a single scan, each sample is
representative of a comparison between two pools of four mice each. p b 0.05 was considered signiﬁcant.
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framework that characterizes development and progression of this
pathological condition.
5. Conclusion
By supplementing fah−/−mice dietwithwater soaked foodwewere
able to prolong their lifespan by at least three times, enabling the study
of molecular changes associated with HT1 progression up to 15 weeks
following NTBC interruption. Our results show that the progression of
HT1 disease can be divided in two events: early and late. The early
stage of HT1 is characterized by the activation of Nrf2, HO-1, eIF2α
and PKC in response to the accumulation of the toxic metabolites asso-
ciatedwith HT1 since it is triggered as soon as 3 days followingNTBC in-
terruption. This early stage is also characterized by the strong induction
of Bcl-2 and the inhibition of Bad and Bax. The late stage of the disease is
associated with the addition of other anti-apoptotic changes as well as
with induction of CHOP, MEK and ERK. These changes were accompa-
niedwith a sustained induction of HO-1 and eIF2α andmost important-
ly with the robust induction of AFP. Therefore HT1 progression is
characterized by a rapid stress response initiated to cope with damages
induced by the accumulation of toxicmetabolites and a late stagewhere
perturbation of cellular homeostasis results in the integration of cell
death resistance and proliferation mechanisms, promoting neoplasticFig. 12. Analysis of AFP expression in fah−/−mice following NTBC discontinuation. (A) Represe
(B) Bar graphs showing quantiﬁcation of AFP expression level compared to expression levels of
expressed as means ± s.d. (n = 4). Western blots are representative of four independent expelesions and tumor growth. In such context proliferating cells seem to
take advantage of ER increased activity to facilitate the folding, assem-
bling and transport of membrane and secretory proteins necessary to
their growth and expansion.Author contribution
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